PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 1, 2015, Pages 39-43

  Burgio, Salvatore L ^a   Conteduca, Vincenza ^a   Rudnas, Britt ^a   Carrozza, Francesco ^b   Campadelli, Enrico ^c   Bianchi, Emanuela ^a   Fabbri, Paolo ^d   Montanari, Marco ^e   Carretta, Elisa ^f   Menna, Cecilia ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b City Hospital   (Italy)

^c Umberto i Hospital   (Italy)

^d AUSL Romagna   (Italy)

^e SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^f Biostatistic and Clinical Trials Unit   (Italy)

Author keywords

Abiraterone; Castration resistant prostate cancer; Outcome; Progression; PSA flare; Survival

Indexed keywords

ABIRATERONE; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; BLOOD; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; DISEASE-FREE SURVIVAL; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84920583134     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.06.010     Document Type: Article

References (24)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. S.S. Sridhar, S.J. Freedland, and M.E. Gleave Castration-resistant prostate cancer: from new pathophysiology to new treatment Eur Urol 65 2014 289 299
3. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
4. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
5. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
7. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
8. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
9. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
10. D.R. Berthold, G.R. Pond, M. Roessner, R. de Wit, M. Eisenberger, and A.I. Tannock Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 2008 2763 2767
11. L. Collette, T. Burzykowski, K.J. Carroll, D. Newling, T. Morris, and F.H. Schröder Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol 23 2005 6139 6148
12. C. Mahler Is disease flare a problem? Cancer 72 1993 3799 3802
13. M. Sugiono, M.H. Winkler, A.A. Okeke, M. Benney, and D.A. Gillatt Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - a pilot study Prostate Cancer Prostatic Dis 8 2005 91 94
14. A. Sella, C.N. Sternberg, I. Skoneczna, and S. Kovel Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer BJU Int 102 2008 1607 1609
15. R. Thuret, C. Massard, and M. Gross-Goupil The postchemotherapy PSA surge syndrome Ann Oncol 19 2008 1308 1311
16. T. Nelius, T. Klatte, W. de Riese, and S. Filleur Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy Int Urol Nephrol 40 2008 97 104
17. P.J. Olbert, A. Hegele, P. Kraeuter, A. Heidenreich, R. Hofmann, and A.J. Schrader Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel Anticancer Drugs 17 2006 993 996
18. A. Angelergues, D. Maillet, and A. Fléchon Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer Eur J Cancer 50 2014 1602 1609
19. C.J. Ryan, A. Londhe, and A. Molina Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302 J Clin Oncol 31 suppl 2013 abstract 5010
20. J. Du, Q. Yang, X.S. Chen, J. Tian, and X. Yao Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy Cancer Chemother Pharmacol 72 2013 1055 1061
21. R. Leibowitz-Amit, A.J. Templeton, and A. Omlin Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer Ann Oncol 25 2014 657 662
22. S.D. Mundlea, A.S. Marathe, and M. Chelladurai Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role Crit Rev Oncol Hematol 86 2013 15 22
23. S.L. Burgio, V. Conteduca, and C. Menna Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone Endocr Relat Cancer 21 2014 487 493
24. S.L. Burgio, F. Fabbri, I.J. Seymour, W. Zoli, D. Amadori, and U. De Giorgi Perspectives on mTOR inhibitors for castration-refractory prostate cancer Curr Cancer Drug Targets 12 2012 940 949